International Journal of Cardiology
Volume 125, Issue 2 , Pages 178-182 , 10 April 2008

Management of atrial fibrillation in heart failure in the elderly

  • Imad Abi nasr

      Affiliations

    • Corresponding Author InformationCorresponding author. University hospital Ambroise Paré, Cardiology Department, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France. Tel.: +33 1 49095626; fax: +33 1 49095344.
    • ,
  • Nicolas Mansencal
    • ,
  • Olivier Dubourg

References 

  1. Kannel WB, Abbott RD, Savage DD, Mcnamara PM. Epidemiological features of chronic atrial fibrillation. N Engl J Med. 1982;306:1018–1022
  2. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy ET. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Mannitoba Follow-up study. Am J Med. 1995;98:466–484
  3. Onundarson PT, Thorgeirson G, Jonmundsson E, Sigfusson N, Hardarson TH. Chronic atrial fibrillation-epidemiological features and 14 year follow-up: a case control study. Eur Heart J. 1987;8:521–527
  4. Garg R, Yusuf S. Epidemiology of congestive cardiac failure. In:  Barnett DB,  Pouler H,  Francis G editor. Congestive heart failure — pathophysiology and treatment. New York: Marcel Dekker; 1993;p. 9–25
  5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N
  6. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636–1644
  7. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D–8D
  8. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–2925
  9. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e257–e354
  10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of a pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457
  11. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-analysis. Ann Intern Med. 1999;131:492–501
  12. Wyse DG, Waldo AL, Di Marco JP, et al. Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  13. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  14. Blackshear JL, Safford RE. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev. 2003;7:366–369
  15. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–865
  16. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–1513
  17. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498–501
  18. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138–1144
  19. Molhoek SG, Bax JJ, Bleeker GB, et al. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol. 2004;94:1506–1509
  20. Hallstrom A, Pratt CM, Greene HL, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol. 1995;25:1250–1257
  21. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–920
  22. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHFSTAT). Circulation. 1998;98:2574–2579
  23. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–1872
  24. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation. 2001;104:292–296
  25. Healey JS, Baranchuk A, Crysal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme and angiotensin receptor blockers. J Am Coll Cardiol. 2005;45:1832–1839
  26. Abi Nasr I, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457–462
  27. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:11139–11143
  28. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373–2383
  29. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, Schaff HV. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg. 2006;82:494–500
  30. The AF–CHF investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF–CHF) trial. Am Heart J. 2002;144:197–607

PII: S0167-5273(07)01623-3

doi: 10.1016/j.ijcard.2007.10.008

International Journal of Cardiology
Volume 125, Issue 2 , Pages 178-182 , 10 April 2008

Article Tools

* Image Usage & Resolution